Literature DB >> 14508879

Vaccines for Moraxella catarrhalis and non-typeable Haemophilus influenzae.

John C McMichael1, Bruce A Green.   

Abstract

The development of vaccines against non-typeable Haemophilus influenzae and Moraxella catarrhalis represents a difficult challenge. Both bacteria are mucosal surface pathogens and protection may require a mucosal immune response. In addition, the surface antigens of non-typeable Haemophilus influenzae are hypervariable and animal models of infection with these bacteria may not be predictive of human efficacy. Vaccine development has focused on conserved surface exposed antigens, including integral outer membrane proteins, pili and other attachment factors, membrane-associated proteins, and lipooligosaccharide-protein conjugates. Several vaccine candidates are described that are antigenically conserved among strains, elicit biologically functional antibodies, and have efficacy in animal models.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14508879

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  6 in total

1.  Genomic sequence of an otitis media isolate of nontypeable Haemophilus influenzae: comparative study with H. influenzae serotype d, strain KW20.

Authors:  Alistair Harrison; David W Dyer; Allison Gillaspy; William C Ray; Rachna Mungur; Matthew B Carson; Huachun Zhong; Jenny Gipson; Mandy Gipson; Linda S Johnson; Lisa Lewis; Lauren O Bakaletz; Robert S Munson
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

2.  Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

3.  Adhesion of Moraxella catarrhalis to human bronchial epithelium characterized by a novel fluorescence-based assay.

Authors:  Hortense Slevogt; Krishna N Tiwari; Bernd Schmeck; Andreas Hocke; Bastian Opitz; Norbert Suttorp; Joachim Seybold
Journal:  Med Microbiol Immunol       Date:  2005-07-30       Impact factor: 3.402

4.  Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model.

Authors:  Pablo D Becker; Gustavo M Bertot; David Souss; Thomas Ebensen; Carlos A Guzmán; Saúl Grinstein
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

5.  Mucosal immunization of mice with recombinant OMP P2 induces antibodies that bind to surface epitopes of multiple strains of nontypeable Haemophilus influenzae.

Authors:  K L Ostberg; M W Russell; T F Murphy
Journal:  Mucosal Immunol       Date:  2008-10-29       Impact factor: 7.313

Review 6.  Interactions of Bacteriophages and Bacteria at the Airway Mucosa: New Insights Into the Pathophysiology of Asthma.

Authors:  Panagiota Tzani-Tzanopoulou; Dimitrios Skliros; Spyridon Megremis; Paraskevi Xepapadaki; Evangelos Andreakos; Nina Chanishvili; Emmanouil Flemetakis; Grigoris Kaltsas; Styliani Taka; Evangelia Lebessi; Anastassios Doudoulakakis; Nikolaos G Papadopoulos
Journal:  Front Allergy       Date:  2021-01-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.